BFLYMEDIUM SIGNALFINANCIAL10-K

BFLY showed strong revenue growth of 19% and dramatically improved operating cash flow, but operating losses widened despite increased capitalization.

The company appears to be in a growth phase with improving cash generation efficiency, as evidenced by operating cash flow improving from -$41.7M to -$12.7M while revenue grew significantly. However, the widening operating losses suggest the company is still investing heavily in growth and has not yet achieved operational profitability, which investors should monitor closely.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

BFLY demonstrated strong top-line growth with revenue increasing 19% to $97.6M, accompanied by a dramatic 69.5% improvement in operating cash flow to -$12.7M, indicating better cash management despite ongoing losses. The company significantly strengthened its balance sheet with cash increasing 69.5% to $150.5M and stockholders' equity growing 16.1%, though current liabilities also rose 35.1%. While operating losses widened to -$86.4M, the substantial improvement in cash flow generation relative to operating performance suggests the company is becoming more efficient at converting operations to cash, positioning it better for continued growth investments.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-99.7%
$651K$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+69.5%
$88.8M$150.5M

Cash position surged 69.5% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+69.5%
-$41.7M-$12.7M

Operating cash flow surged 69.5% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
+35.1%
$48.2M$65.1M

Current liabilities surged 35.1% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+29.3%
$192.6M$249.1M

Current assets grew 29.3% — improving short-term liquidity or inventory/receivables build.

Accounts Receivable
Balance Sheet
+28.6%
$20.8M$26.7M

Receivables grew 28.6% — monitor days sales outstanding for collection efficiency.

Capital Expenditure
Cash Flow
+24.3%
$2.7M$3.3M

Capex increased 24.3% — ongoing investment in capacity or infrastructure for future growth.

Revenue
P&L
+19%
$82.1M$97.6M

Revenue growing 19% — solid top-line momentum, watch margins for quality of growth.

Operating Income
P&L
-16.1%
-$74.4M-$86.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Stockholders Equity
Balance Sheet
+16.1%
$168.8M$196.0M

Equity base grew 16.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 19, 2026, the registrant had 228,205,930 shares of Class A common stock outstanding and 26,426,937 shares of Class B common stock outstanding.
and foreign laws, which are subject to change and could adversely affect our business; the pricing of our products and services and reimbursement for medical procedures conducted using our medical products and services; changes in applicable laws or regulations; our ability to protect or enforce our intellectual property rights; and economic downturns and political and market conditions beyond our control.
We are dependent upon the success of our sales and customer acquisition and retention strategies.
Acquisitions, joint ventures, or other strategic transactions, including in connection with our Butterfly Embedded program, could disrupt our business, cause dilution to our stockholders, and otherwise harm our business.
Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted computer crimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our business.
+7 more — sign up free →
REMOVED
As of February 13, 2025, the registrant had 216,496,214 shares of Class A common stock outstanding and 26,426,937 shares of Class B common stock outstanding.
and foreign laws, which are subject to change and could adversely affect our business; the pricing of our products and services and reimbursement for medical procedures conducted using our products and services; changes in applicable laws or regulations; our ability to protect or enforce our intellectual property rights; the ability to maintain the listing of our Class A common stock on the New York Stock Exchange; and economic downturns and political and market conditions beyond our control.
We will be dependent upon the success of our sales and customer acquisition and retention strategies.
Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted computer crimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our business If we are unable to protect our intellectual property, our ability to maintain any technological or competitive advantage over our competitors and potential competitors would be adversely impacted, and our business may be harmed.
The Company s outstanding warrants became exercisable for the Company s Class A common stock on May 26, 2021.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →